Karen Akinsanya - 14 Apr 2025 Form 4 Insider Report for Schrodinger, Inc. (SDGR)

Role
President of R&D, Therapeutics
Signature
/s/ Donald Shum, as attorney-in-fact for Karen Akinsanya
Issuer symbol
SDGR
Transactions as of
14 Apr 2025
Net transactions value
-$366,726
Form type
4
Filing time
15 Apr 2025, 16:31:21 UTC
Previous filing
04 Mar 2025
Next filing
25 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SDGR Common Stock Options Exercise $43,077 +13,378 +86% $3.22 29,003 14 Apr 2025 Direct F1, F2
transaction SDGR Common Stock Options Exercise $9,767 +3,345 +12% $2.92 32,348 14 Apr 2025 Direct F1, F2
transaction SDGR Common Stock Sale $210,391 -8,378 -26% $25.11 23,970 14 Apr 2025 Direct F1, F2, F3
transaction SDGR Common Stock Sale $125,554 -5,000 -21% $25.11 18,970 14 Apr 2025 Direct F1, F2, F4
transaction SDGR Common Stock Sale $83,625 -3,345 -18% $25.00 15,625 14 Apr 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SDGR Stock Option (right to buy) Options Exercise $0 -13,378 -100% $0.000000 0 14 Apr 2025 Common Stock 13,378 $3.22 Direct F1, F5
transaction SDGR Stock Option (right to buy) Options Exercise $0 -3,345 -100% $0.000000 0 14 Apr 2025 Common Stock 3,345 $2.92 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2024.
F2 Includes 15,625 unvested RSUs.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (4) of this form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (4) of this form 4.
F5 The option was granted on August 3, 2018 and is fully vested.
F6 The option was granted on October 10, 2017 and is fully vested.